BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
61.80
-0.93 (-1.48%)
At close: Nov 7, 2025, 4:00 PM EST
63.03
+1.23 (1.99%)
Pre-market: Nov 10, 2025, 6:10 AM EST
BridgeBio Pharma Stock Forecast
Stock Price Forecast
The 18 analysts that cover BridgeBio Pharma stock have a consensus rating of "Strong Buy" and an average price target of $74.28, which forecasts a 20.19% increase in the stock price over the next year. The lowest target is $49 and the highest is $110.
Price Target: $74.28 (+20.19%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BridgeBio Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 7 | 7 | 7 | 9 | 9 |
| Buy | 8 | 9 | 9 | 9 | 9 | 9 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 16 | 16 | 16 | 18 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $76 → $77 | Buy | Maintains | $76 → $77 | +24.60% | Nov 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +45.63% | Nov 3, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $55 → $100 | Strong Buy | Maintains | $55 → $100 | +61.81% | Oct 31, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $60 → $95 | Strong Buy | Maintains | $60 → $95 | +53.72% | Oct 30, 2025 |
| Raymond James | Raymond James | Buy Reiterates $69 → $71 | Buy | Reiterates | $69 → $71 | +14.89% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
495.56M
from 221.90M
Increased by 123.32%
Revenue Next Year
859.59M
from 495.56M
Increased by 73.46%
EPS This Year
-3.55
from -2.88
EPS Next Year
-1.98
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 593.7M | 1.2B | |||
| Avg | 495.6M | 859.6M | |||
| Low | 429.2M | 668.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 167.5% | 134.1% | |||
| Avg | 123.3% | 73.5% | |||
| Low | 93.4% | 34.9% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.01 | -0.71 | |||
| Avg | -3.55 | -1.98 | |||
| Low | -3.79 | -2.79 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.